NA
EIDX

Neuburgh Advisers’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Neuburgh Advisers’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,090
Closed -$65K – 946
2019
Q2 		$65K Hold
2,090
– – ﹤0.01% 842
2019
Q1 		$49K Hold
2,090
– – ﹤0.01% 853
2018
Q4 		$29K Sell
2,090
-7,590
-78% -$95.8K ﹤0.01% 849
2018
Q3 		$97K Buy
9,680
+6,182
+177% +$102K ﹤0.01% 809
2018
Q2 		$71K Buy
+3,498
New +$73.3K ﹤0.01% 821

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Neuburgh Advisers's EIDX Position: Q3 2019 in Review

Neuburgh Advisers sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2019, closing a stake of 2,090 shares — an estimated $65K sold.

Neuburgh Advisers first reported a position in EIDX in Q2 2018 and held it in 5 quarters. The position peaked at $97K in Q3 2018. 79 funds tracked by Wall St. Rank hold EIDX as of Q3 2019.

  • Neuburgh Advisers reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Neuburgh Advisers sold 2,090 Eidos Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $65K.
  • Neuburgh Advisers first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
  • Neuburgh Advisers's Eidos Therapeutics, Inc. Common Stock position peaked at $97K in Q3 2018.
  • 79 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.